ストックスクリーナーアプリを入手
7.47
2.60%
-0.1995
前日終値:
$7.6695
開ける：
$7.68
24時間の取引高:
18,950
Relative Volume:
0.78
時価総額：
$20.84M
収益：
$6.56M
当期純損益:
$-14.92M
株価収益率:
-13.83
EPS:
-0.54
ネットキャッシュフロー:
$-33.87M
1週間 パフォーマンス:
-4.84%
1か月 パフォーマンス:
+55.62%
6か月 パフォーマンス:
+45.05%
1年 パフォーマンス:
+1.06%
1日の値動き範囲:
$7.35
$7.68
1週間の範囲:
$6.8101
$8.26
52週間の値動き範囲:
$3.34
$16.50
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
SLGL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
7.47 | 21.87M | 6.56M | -14.92M | -33.87M | -0.54 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-19 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2019-12-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-31 | 繰り返されました | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd (SLGL) 最新ニュース
SEC Form 424B3 filed by Sol-Gel Technologies Ltd. - Quantisnow
Will Sol-Gel Deliver The First Preventive Treatment For Gorlin Syndrome? - RTTNews
Sol-Gel Technologies (NASDAQ:SLGL) Stock Price Down 39.5% – Should You Sell? - Defense World
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference - Barchart.com
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
Sol-Gel Technologies Announces Reverse Share Split to Regain Nasdaq Compliance - TipRanks
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA - Barchart.com
Insider Buys Additional US$98k In Sol-Gel Technologies Stock - simplywall.st
Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares - Yahoo Finance
This Sol-Gel Technologies Insider Increased Their Holding In The Last Year - Yahoo Finance
Sol-Gel Technologies announces 10-for-1 reverse stock split By Investing.com - Investing.com Nigeria
Sol-Gel Technologies (SLGL) Announces 10-for-1 Reverse Stock Spl - GuruFocus
Sol-Gel Technologies announces 10-for-1 reverse stock split - Investing.com
Sol-Gel Announces Reverse Share Split - TradingView
Basal Cell Nevus Syndrome Treatment Market 2032: EMA, PDMA, FDA - openPR.com
Sol-Gel Technologies Ltd [SLGL] Investment Guide: What You Need to Know - knoxdaily.com
Did Sol-Gel Technologies Ltd (SLGL) perform well in the last session? - uspostnews.com
Sol-Gel secures $16 million, extends cash runway By Investing.com - Investing.com Canada
Sol-Gel Technologies Secures $16 Million Deal with Mayne Pharma for U.S. Rights to EPSOLAY and TWYNEO - TipRanks
Sol-Gel secures $16 million, extends cash runway - Investing.com Australia
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - The Manila Times
Sol-Gel's Strategic Pivot: $16M Product Sale Funds Promising Cancer Drug Development - Stock Titan
XBiotech Inc. (NASDAQ:XBIT) Shares Sold by American Century Companies Inc. - Defense World
Raymond James Financial Inc. Invests $101,000 in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) - Defense World
Raymond James Financial Inc. Purchases New Shares in Stereotaxis, Inc. (NYSEAMERICAN:STXS) - Defense World
American Century Companies Inc. Sells 20,635 Shares of AxoGen, Inc. (NASDAQ:AXGN) - Defense World
Sol-Gel Technologies Ltd. (4SG.F) latest stock news and headlines - Yahoo
Investors Don't See Light At End Of Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Tunnel And Push Stock Down 31% - simplywall.st
(PDF) Synthesis and Characterization of CZTS Thin Films by Sol-Gel Method without Sulfurization - ResearchGate
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal - TipRanks
(PDF) NaFePO4 Particles as a Cathode of Sodium Ion-Battery via Sol-Gel Method: A Review on Synthesis - ResearchGate
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Sol Gel Technologies Ltd expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Retinoic Acid Receptor Alpha Market Unlocking Growth Opportunities Through Smart Solutions - expressvartha.in
Uremic Pruritus Clinical and Non-Clinical Studies, Key - openPR
Sol-Gel Technologies (SLGL) to Release Quarterly Earnings on Wednesday - Defense World
Key Driver Transforming The Rosacea Market 2025: Rising Skin Disease Prevalence Fuels Growth In The Rosacea... - WhaTech
Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR
Palmoplantar Keratoderma Clinical and Non-Clinical Studies, - openPR
Sol-Gel Coatings Market Trends, Insights, and Opportunities through 2032 - newstrail.com
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Sol-Gel Technologies Schedules Shareholder Meeting to Vote on Key Proposals - TipRanks
Basal Cell Nevus Syndrome Treatment Market Size in the 7MM - openPR
Biotech Stocks Facing FDA Decision In August 2021 - RTTNews
Sol-Gel Technologies Ltd (SLGL) Shares Decline Despite Market Challenges - The News Heater
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Not Doing Enough For Some Investors As Its Shares Slump 51% - Simply Wall St
Sol Gel Technologies Ltd (SLGL) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):